184 related articles for article (PubMed ID: 34382416)
21. FOLFIRINOX is a cost-effective combination chemotherapy in first-line for advanced pancreatic Cancer.
Giuliani J; Bonetti A
Pancreatology; 2019 Mar; 19(2):325-330. PubMed ID: 30704852
[TBL] [Abstract][Full Text] [Related]
22. The economic burden of metastatic pancreatic cancer.
Malangone-Monaco E; Doleh Y; Cole A; Noxon V; Antico G; Pishvaian MJ
Pancreatology; 2020 Oct; 20(7):1434-1441. PubMed ID: 32967794
[TBL] [Abstract][Full Text] [Related]
23. Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer.
McBride A; MacDonald K; Fuentes-Alburo A; Abraham I
J Med Econ; 2021; 24(1):743-756. PubMed ID: 34003067
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim.
Kang KW; Lee BH; Jeon MJ; Yu ES; Kim DS; Lee SR; Sung HJ; Choi CW; Park Y; Kim BS
Cancer Med; 2020 Sep; 9(17):6102-6110. PubMed ID: 32633471
[TBL] [Abstract][Full Text] [Related]
25. Managing the economic impact of advanced pancreatic cancer.
Soefje SA
Am J Manag Care; 2019 Jan; 25(1 Suppl):S11-S16. PubMed ID: 30681820
[TBL] [Abstract][Full Text] [Related]
26. A retrospective review of the real-world experience of the Pegfilgrastim biosimilar (Lapelga®) to the reference biologic (Neulasta®).
Wong G; Zhang L; Majeed H; Razvi Y; DeAngelis C; Lam E; McKenzie E; Wang K; Pasetka M
J Oncol Pharm Pract; 2022 Jan; 28(1):5-16. PubMed ID: 33215563
[TBL] [Abstract][Full Text] [Related]
27. Biosimilar pegfilgrastim may offer affordable treatment options for patients in France: a budget impact analysis on the basis of clinical trial and real-world data.
Yang J; Liu R; Granghaud A; Zaidi O; Stephens J
J Med Econ; 2021; 24(1):665-674. PubMed ID: 33904357
[TBL] [Abstract][Full Text] [Related]
28. Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
Blackwell K; Gascon P; Jones CM; Nixon A; Krendyukov A; Nakov R; Li Y; Harbeck N
Ann Oncol; 2017 Sep; 28(9):2272-2277. PubMed ID: 28637287
[TBL] [Abstract][Full Text] [Related]
29. Cost comparison of filgrastim versus pegfilgrastim and pegfilgrastim biosimilars for inpatient prophylaxis of febrile neutropenia.
Singer K; Forshay CM; Kennerly-Shah J
J Oncol Pharm Pract; 2023 Oct; 29(7):1695-1701. PubMed ID: 36544396
[TBL] [Abstract][Full Text] [Related]
30. Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim.
Grewal S; Ramsey S; Balu S; Carlson JJ
Expert Rev Pharmacoecon Outcomes Res; 2018 Aug; 18(4):447-454. PubMed ID: 29757040
[TBL] [Abstract][Full Text] [Related]
31. A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial.
Blackwell K; Donskih R; Jones CM; Nixon A; Vidal MJ; Nakov R; Singh P; Schaffar G; Gascón P; Harbeck N
Oncologist; 2016 Jul; 21(7):789-94. PubMed ID: 27091420
[TBL] [Abstract][Full Text] [Related]
32. Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma.
MacDonald K; Pondel M; Abraham I
J Med Econ; 2024; 27(sup3):1-8. PubMed ID: 38488887
[TBL] [Abstract][Full Text] [Related]
33. A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer.
Ozaka M; Ishii H; Sato T; Ueno M; Ikeda M; Uesugi K; Sata N; Miyashita K; Mizuno N; Tsuji K; Okusaka T; Furuse J
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1017-1023. PubMed ID: 29633005
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and Cost-effectiveness of Pegfilgrastim for Preventing Febrile Neutropenia During Docetaxel, Cisplatin, and 5-Fluorouracil Therapy for Esophageal Cancer.
Kurogochi T; Matsumoto A; Nyumura Y; Tanishima Y; Nakayoshi T; Okamoto T; Yano F; Eto K
Anticancer Res; 2023 May; 43(5):2293-2298. PubMed ID: 37097646
[TBL] [Abstract][Full Text] [Related]
35. Achieving white blood cell equity: are the safety profiles of biosimilar and reference pegfilgrastims comparable?
Loaiza-Bonilla A; Page RD
Future Oncol; 2024 Jan; 20(3):145-158. PubMed ID: 37609795
[TBL] [Abstract][Full Text] [Related]
36. Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Fleeman N; Abdulla A; Bagust A; Beale S; Richardson M; Stainthorpe A; Boland A; Kotas E; McEntee J; Palmer D
Pharmacoeconomics; 2018 Mar; 36(3):289-299. PubMed ID: 29178025
[TBL] [Abstract][Full Text] [Related]
37. Cost comparison of outpatient treatment with granulocyte colony-stimulating factors (G-CSF) in Germany.
Hadji P; Kostev K; Schröder-Bernhardi D; Ziller V
Int J Clin Pharmacol Ther; 2012 Apr; 50(4):281-9. PubMed ID: 22456299
[TBL] [Abstract][Full Text] [Related]
38. Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis.
Mansell K; Bhimji H; Eurich D; Mansell H
BMC Health Serv Res; 2019 Nov; 19(1):827. PubMed ID: 31718624
[TBL] [Abstract][Full Text] [Related]
39. Pegfilgrastim-jmdb/MYL-1401H: A Pegfilgrastim Biosimilar.
Hoy SM
BioDrugs; 2019 Feb; 33(1):117-120. PubMed ID: 30701419
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
